FIKAX
Price
$47.45
Change
-$0.00 (-0.00%)
Updated
Sep 18 closing price
IENAX
Price
$29.47
Change
-$0.00 (-0.00%)
Updated
Sep 18 closing price
Ad is loading...

FIKAX vs IENAX

Header iconFIKAX vs IENAX Comparison
Open Charts FIKAX vs IENAXBanner chart's image
Fidelity Advisor Energy Z
Price$47.45
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Invesco Energy A
Price$29.47
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
FIKAX vs IENAX Comparison Chart
Loading...
VS
FIKAX vs. IENAX commentary
Sep 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FIKAX is a Buy and IENAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
FIKAX has more cash in the bank: 1.24B vs. IENAX (450M). FIKAX (1.99) and IENAX (1.90) have matching dividends . FIKAX was incepted earlier than IENAX: FIKAX (6 years) vs IENAX (22 years). IENAX is a more actively managed with annual turnover of: 52.00 vs. FIKAX (21.00). FIKAX has a lower initial minimum investment than IENAX: FIKAX (0) vs IENAX (1000). IENAX annual gain was more profitable for investors over the last year : -0.69 vs. FIKAX (-3.81). FIKAX return over 5 years is better than : 82.57 vs. IENAX (71.75).
FIKAXIENAXFIKAX / IENAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence6 years22 years-
Gain YTD5.0245.32594%
Front LoadN/AN/A-
Min. Initial Investment01000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.24B450M276%
Annual Yield % from dividends1.991.90105%
Returns for 1 year-3.81-0.69549%
Returns for 3 years99.7291.72109%
Returns for 5 years82.5771.75115%
Returns for 10 yearsN/A-32.84-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
APGE53.342.70
+5.33%
Apogee Therapeutics
KEY16.590.02
+0.12%
KeyCorp
SMP33.36-0.83
-2.43%
Standard Motor Products
EMKR1.07-0.03
-2.73%
EMCORE Corp
MCRB1.05-0.05
-4.55%
Seres Therapeutics